BMS-813160 is a potent and selective CCR2 (C-C chemokine receptor type 2) antagonist primarily investigated for its potential therapeutic applications in oncology. CCR2 plays a crucial role in tumor growth, metastasis, and immune response modulation by recruiting pro-tumorigenic monocytes to the tumor microenvironment. By inhibiting CCR2, BMS-813160 aims to disrupt this microenvironment, limiting cancer progression and enhancing immunotherapies like PD-1 inhibitors. Preclinical studies highlight its utility in combination treatments for solid tumors, reducing immunosuppressive signals and promoting anti-tumor immunity. Clinical trials are ongoing to assess safety, pharmacokinetics, and efficacy as a novel cancer therapy. It has also shown promise in inflammatory conditions like fibrosis.